Patent ID: 8354229

Claim:
A method of determining survival prognosis in a subject having, or suspected of having acute myeloid leukemia (AML), comprising: obtaining a test sample from subject having, or suspected of having AML, wherein the sample is extracted from at least one of: blood, bone marrow, and tissue suspected of having leukemic cells, measuring, by hybridization assay, the level of at least one miR gene product of miR-25 in the test sample, comparing the level of miR-25 gene product in the test sample relative to a control level of miR-25 gene product, and determining the subject's survival prognosis, wherein if the level of the miR-25 gene product in the test sample is high relative to the level of a corresponding miR-25 gene product in the control sample, the subject is determined to have a shorter overall survival prognosis.